ISPOR's Short Course Program Is Now Virtual

The renowned ISPOR Short Course Program is now being offered virtually. The program is designed to enhance knowledge and techniques in core health economics and outcomes research (HEOR) topics as well as emerging trends in the field. Taught by expert faculty, short courses topics are offered across 7 topical tracks and range in skill level from introductory to experienced.

Upcoming Virtual Short Courses

Expand your HEOR knowledge from the safety and comfort of your home or office. ISPOR's expert short course faculty are presenting the same curriculum that has historically been offered at ISPOR in-person events through an interactive virtual experience. The courses are not recorded so attendance in the live-broadcast is important. These hand-picked virtual courses, along with their electronic course books, provide a solid foundation in essential methodologies and emerging issues.

Registration Rates

*NOTE: All dates and times are based on Korea Standard Time (KST). Click time zone conversion.

29 September 2020:
Patient-Reported Outcomes Measures (PROMs): Cross-Cultural Development and Validation

LEVEL - Introductory. This course is designed for those with limited experience with quality of life/PRO studies.
TRACK - Patient-Centered Research
TIME: 9:00AM KST-2:00PM KST *(Korea Standard Time) (1-hour break from 11:00AM KST – 12:00PM KST)
Course Start Times per Time Zone:
9:00AM KST (Tuesday, 29 September)
8:00PM EDT (Monday, September 28)
5:00AM PDT (Monday, September 28)
1:00AM BST (Tuesday, 29 September)

Click for time zone conversion


This course will introduce the definitions and concepts, methodologies, and practical methods for measuring patient-reported outcomes will be presented. The value of patient-reported outcomes assessment will be discussed. A strategy to aid in selecting appropriate instruments and the translation processes will be presented with considerations for regional needs. Instrument development and validation will be discussed using practical examples and exercises, including ISPOR Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures.



Bruce Crawford, MPH, MA
Vice President, Real World Evidence & Insights
Syneos Health
Chūō-ku, Japan


12-15 October 2020 (4-Day Course):Using Multi-Criteria Decision Analysis in Healthcare Decision Making: Approaches & Applications

LEVEL - Introductory
TRACK - Health Technology Assessment
TIME:  Each Day 9:00AM KST-10:00 AM KST *(Korea Standard Time)
Course Start Times per Time Zone:
9:00AM KST (Monday, 12 October)
8:00PM EDT (Sunday, October 11)
5:00AM PDT (Sunday, October 11)
1:00AM BST (Monday, 12 October)

Click for time zone conversion


Many healthcare decisions—such as, portfolio optimization, benefit-risk assessment (BRA), health technology assessment (HTA), and shared decision making (SDM)—require a careful assessment of the underlying options and the criteria used to judge these options. This assessment can be challenging given the trade-offs between multiple value criteria. In light of this, many decision makers have begun investigating the use of multi-criteria decision analysis (MCDA) in support of these decisions. This course provides an introduction to MCDA for health care. The course will focus on the use of MCDA for HTA and will be organized around the following parts: (1) Introduction to MCDA: What is it and how is it being use in HTA?; (2) Implementing MCDA 1: Practical tips when implementing MCDA; (3) Implementing MCDA 2: Methodological options when designing an MCDA; and (4) Using MCDA for HTA. Challenges and possible solutions. These parts are designed to familiarize participants with the steps involved in undertaking an MCDA, the alternative ways of implementing these steps, and good practice guidelines. The course will also review the current MCDA HTA landscape, including current use of MCDA for HTA and the challenges this poses. The course is designed for those unfamiliar with MCDA, but who have a basic understanding of other evaluation methodologies.



Kevin Marsh, PhD
Executive Director, Evidera, Newport Pagnell, BKM,
Great Britain, UK

Ji-Hye Byun, PhD
Associate Research Fellow, Pharmaceutical Policy Research Division,
Health Insurance Review & Assessment Service (HIRA)
Wonju-Si, Gangwon-Do, Republic of South Korea



16 October 2020:Study Design with Real-World Data

LEVEL - Introductory
TRACK - Real World Data & Information Systems
TIME: 9:00AM KST – 2:00PM KST *(Korea Standard Time) (1-hour break from 11:00AM KST – 12:00PM KST)
Course Start Times per Time Zone:
9:00AM KST (Friday, 16 October)
8:00PM EDT (Thursday, October 15)
5:00AM PDT (Thursday, October 15)
1:00AM BST (Friday, 16 October)

Click for time zone conversion


The proliferation of real-world data (RWD) is providing researchers with greater opportunity to study clinical outcomes in diverse approaches outside of traditional randomized clinical trials. These real-world data based on observational studies can include retrospective studies (eg, clinical/hospital record/chart review, administrative data/insurance claims database studies, and electronic medical records data studies), or prospective studies (eg, registries, health surveys, prospective observational studies, or post-authorization safety studies). While RWD studies have great potential to study once-unattainable questions, they also pose their own set of challenges. This course will introduce the different types of RWD-based studies and address their fundamental design strategies as well as inherent challenges such as validity, quality of data and confounding. Presenters will also introduce study design aspects such as the research question, data sources, population, sample size, endpoints, and internal and external validity considerations.



Jeff J. Guo, PhD
Professor, Division of Pharmacy Practice & Administrative Sciences
University of Cincinnati
Cincinnati, OH, USA

Xin Sun, PhD
Professor, Chinese Evidence-Based Medicine Center
West China Hospital of Sichuan University
Chengdu, China


19 October 2020:Transferability of Cost-Effectiveness Data Between Countries

LEVEL - Intermediate
TRACK - Economic Evaluation
TIME: 9:00AM KST – 2:00PM KST *(Korea Standard Time) (1-hour break from 11:00 KST – 12:00PM KST)
Course Start Times per Time Zone:
9:00AM KST (Monday, 19 October)
8:00PM EDT (Sunday, October 18)
5:00AM PDT (Sunday, October 18)
1:00AM BST (Monday, 19 October)

Click for time zone conversion


Economic evaluation data have become a key requirement in pharmaceutical reimbursement submission dossiers for many countries. While most of the data are produced for “initial launch countries,” payers from subsequent launch countries are increasingly requiring estimates that are relevant or generalizable to their own populations to be considered valid. Since cost and resource limitations prevent technology producers from conducting cost effectiveness studies in every launch country, and local assessors have their own limitations, methods for adapting these global models become highly needed. This course will introduce methodology for adaptation of international cost-effectiveness models to local jurisdictions, providing guidance on potential model selection and key considerations from stakeholder perspectives, with reference to the ISPOR Good Practices on Economic Data Transferability Task Force. Principle methodology will be supplemented by practical case studies.



Eun-Young Bae, PhD
Professor, Gyeongsang National University
Jinju, Republic of South Korea

Jasmine Pwu, PhD
Director of National Hepatitis C Program Office
Ministry of Health and Welfare
Taipei, Taiwan


21 October 2020:Risk-Sharing/Performance-Based Schemes for Drugs & Medical Devices

LEVEL - Intermediate. It will be helpful for individuals to be familiar with both the key determinants of pharmaceutical pricing and the main international health systems.
TRACK - Health Policy & Regulatory
TIME: 9:00AM KST – 2:00PM KST *(Korea Standard Time) (1-hour break from 11:00 KST – 12:00PM KST)
Course Start Times per Time Zone:
9:00AM KST (Wednesday, 21 October)
8:00PM EDT (Tuesday, October 20)
5:00AM PDT (Tuesday, October 20)
1:00AM BST (Wednesday, 21 October)

Click for time zone conversion


There is significant and growing interest among both the payers and producers of medical products for arrangements that involve a “pay-for-performance” or “risk-sharing” element. These payment schemes involve a plan by which the performance of the product is tracked in a defined patient population over a specified period and the level of reimbursement is tied by formula to the outcomes achieved. Although these agreements have an intrinsic appeal, there can be substantial barriers to their implementation. Theory and practice, including incentives and barriers, will be analyzed along with several country-specific examples including those from Asia Pacific. It will be helpful for individuals to be familiar with both the key determinants of pharmaceutical pricing and the main international health systems.



Louis P. Garrison, PhD
Professor Emeritus, Department of Pharmacy
University of Washington
The Comparative Health Outcomes, Policy, and Economics Institute,
Seattle, WA, USA

Adrian Towse, MA, MPhil
Director Emeritus & Senior Research Fellow
Office of Health Economics
London, UK

Dong-Churl Suh, RPh, MBA, PhD
Professor and Director
Pharmaceutical Economics and Policy
College of Pharmacy Chung-Ang University
Seoul, South Korea


27 October 2020:Health Technology Assessment for Rare Diseases

LEVEL - Introductory
TRACK - Health Technology Assessment
TIME: 9:00AM KST – 2:00PM KST *(Korea Standard Time) (1-hour break from 11:00 KST – 12:00PM KST)
Course Start Times per Time Zone:
9:00AM KST (Tuesday, 27 October)
8:00PM EDT (Monday, October 26)
5:00AM PDT (Monday, October 26)
1:00AM BST (Tuesday, 27 October)

Click for time zone conversion


Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to assess the value of a health technology at different points in its lifecycle with the aim to inform decision-making to promote an equitable, efficient, and high-quality health system. While these systematic appraisal processes can make decision making for most medical technologies easier and more transparent, technologies aimed at rare diseases, such as “orphan drugs,” present unique challenges to the HTA process. This class of drugs often carries high costs, aims to fill an unmet demand, and often lacks clear comparators. Other aspects such as disease severity, data constraints, and small population size all require payers and assessors to take special approaches to value assessment. This course will outline the unique situation that orphan drugs pose to health technology assessment processes and will teach the participant different protocols and criteria for conduct, citing real-world cases globally. Issues surrounding evidence requirements, cost-effectiveness, and stakeholder value judgment will be addressed.



Hansoo Kim, MSc
Monash University
Melbourne, Victoria, Australia

Hwee Lin Wee, PhD
Assistant Professor
National University of Singapore


30 October 2020:Budget Impact Analysis I: A 6-Step Approach

LEVEL - Intermediate
TRACK - Economic Evaluation
TIME: 9:00AM KST – 2:00PM KST *(Korea Standard Time) (1-hour break from 11:00 KST – 12:00PM KST)
Course Start Times per Time Zone:
9:00AM KST (Friday, 30 October)
8:00PM EDT (Thursday, October 29)
5:00AM PDT (Thursday, October 29)
1:00AM BST (Friday, 30 October)

Click for time zone conversion


This course will describe the methods used to estimate the budget impact of a new healthcare technology and will present 6 basic steps for estimating budget impact: (1) estimating the target population; (2) selecting a time horizon; (3) identifying current and projected treatment mix; (4) estimating current and future drug costs; (5) estimating change in disease-related costs; and (6) estimating and presenting changes in annual budget impact and health outcomes. Both static and dynamic methods for estimating the budget and health impact of adding a new drug to a health plan formulary will be presented. These six steps will be illustrated using actual budget impact models. This course is designed for those with some experience with pharmacoeconomic analysis.



C. Daniel Mullins, PhD
Pharmaceutical Health Services Research
University of Maryland School of Pharmacy
Baltimore, MD, USA

Jianwei Xuan MD, PhD
Professor and Director
Health Economic Research Institute
Sun Yat-sen University, Guangzhou, China


Registration Rates

8 Hour | 4 Day  Short CourseNon-member
Member Rate
Standard $640$512
Full-Time Students (must provide current enrollment docs)$200$160
Patient Representative$200$160
4 Hour | 1 Day Short CourseNon-memberMember Rate
Full-Time Students (must provide current enrollment docs)$100$80
Patient Representative$100$80

The cancellation date for short courses is 2 weeks before the course. All cancellation requests must be made in writing and emailed to ISPOR Registration. A $50.00 cancellation fee applies. After the 2 week period no refund can be provided.

Additional Short Course Program Details

Short Course Tracks

ISPOR short courses are offered across the following topical tracks:

  • Economic Evaluation
  • Methodological & Statistical Research
  • Study Approaches
  • Real World Data & Information Systems
  • Patient-Centered Research
  • Health Policy & Regulatory
  • Health Technology Assessment

Short Course Core Curriculum

ISPOR short course core curriculum is defined as essential curriculum for professional success in the HEOR field; courses/topic areas that are offered at all conferences and the building blocks of a fundamental curriculum that can be applied to future educational programs/offerings.

  • Economic Evaluation
    • Introduction to Health Economics and Outcomes Research
    • Statistical Methods for Health Economics and Outcomes Research
    • Budget Impact Analysis I – A 6-Step Approach
  • Methodology & Statistical Methods
    • Introduction to Modeling Methods
  • Study Approaches
    • Introduction to the Design & Database Analysis of Observational Studies of Treatment Effects
    • Meta-analysis & Systematic Literature Review
    • Network Meta-Analysis
  • Patient-Centered Research
    • Introduction to Patient-Reported Outcomes
    • Utility Measures
  • Health Policy & Regulatory
    • Elements of Pharmaceutical/Biotech Pricing
    • Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
    • Global Payers/US Payers
  • Health Technology Assessment
    • Introduction to Health Technology Assessment


Need More Information or Have Questions?

Contact us for more information on ISPOR education and training.

Contact Us

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now